drugset
drugset / Trial / NCT04993729

Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

NCT04993729 ↗

Phase 3 Completed 853 enrolled Tasly Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The specific aim of this double blind, randomized phase III trial is to evaluate the safety and efficacy of T89 in preventing Acute Mountain Sickness (AMS) and relieving the symptoms of AMS after rapid ascent.

Timeline

Start
2021-07-21
Primary completion
2023-05-26
Completion
2023-05-26

Drugs

EvaluationDrugModalityDoseRoute
Subject T89 Traditional medicine (herbal / TCM) 225 mg Oral
Subject T89 Traditional medicine (herbal / TCM) 300 mg Oral

Indications

acute mountain sickness